Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer

Etienne Giroux Leprieur1,2,3, Bhairavi Tolani1, Hui Li1

  • 1Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.

Oncotarget
|December 22, 2017
PubMed

Insights

Researchers identified Sonic Hedgehog-positive (Shh+) cells in non-small cell lung cancer (NSCLC) that exhibit cancer stem cell (CSC) traits and chemoresistance. These Shh+ cells promote tumor growth and are linked to poor prognosis in NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The Sonic Hedgehog (Shh) pathway's role in non-small cell lung cancer (NSCLC) activation is not well understood.
  • A subset of Shh-positive (Shh+) cells has been observed in NSCLC cell lines.

Purpose of the Study:

  • To characterize the functional properties and clinical significance of Shh+ cells in NSCLC.
  • To investigate the therapeutic potential of targeting the Shh pathway in NSCLC.

Main Methods:

  • Fluorescence Activated Cell Sorting (FACS) to isolate Shh+ and Shh- cells from NSCLC lines.
  • Gene expression analysis (qRT-PCR, microarray), in vitro functional assays, and in vivo xenograft models.
  • Treatment with chemotherapy and a Shh signaling inhibitor (GDC0449), followed by analysis in human NSCLC samples.

Main Results:

  • Shh+ cells express full-length, membrane-bound Shh protein and promote proliferation and migration of Shh- cells via paracrine signaling.
  • Shh+ cells demonstrate chemoresistance and possess cancer stem cell (CSC) characteristics both in vitro and in vivo.
  • Shh pathway inhibition reduced CSC features, and a high percentage of Shh+ cells correlated with poor prognosis in early-stage NSCLC.

Conclusions:

  • This study identifies abnormal membrane-bound Shh as a marker for cancer stem cells in NSCLC.
  • Shh+ cells represent a chemoresistant, prognostically significant population in NSCLC.
  • Targeting the Shh pathway may offer a therapeutic strategy for NSCLC by suppressing CSC properties.